Symptom Distress, Including Pain, Predicts Lung Ca Survival

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

WINNIPEG, Canada-Clinical trials have shown that the level of symptom distress at the time of lung cancer diagnosis can predict survival, and now a study performed in an ambulatory setting has confirmed this finding. Patients with higher symptom distress scores are likely to die more quickly than those with lower scores, report University of Manitoba researchers Lesley F. Degner, RN, PhD, and Jeffrey A. Sloan, PhD.

WINNIPEG, Canada-Clinical trials have shown that the level ofsymptom distress at the time of lung cancer diagnosis can predictsurvival, and now a study performed in an ambulatory setting hasconfirmed this finding. Patients with higher symptom distressscores are likely to die more quickly than those with lower scores,report University of Manitoba researchers Lesley F. Degner, RN,PhD, and Jeffrey A. Sloan, PhD.

They note that clinicians can use this information to counselpatients and families and discuss life completion issues. In addition,the data raise the interesting question of whether interventionsto palliate symptoms could influence survival.

The study involved 434 newly diagnosed cancer patients from twoclinics in Winnipeg, including 82 with lung cancer. Only 13% ofthe sample had been offered clinical trials, and 10% accepted.

Patients completed a symptom distress measure consisting of 13symptoms and scaled from 1 (normal or no distress) to 5 (severedistress). Survival analysis was conducted 5 years after the startof the initial data collection, at which time only 13 of the original82 lung cancer patients were alive.

Overall, symptom distress was very low in this group, with a meanscore of 23.06 out of a theoretical range of 13 to 65. The mosttroubling symptoms were fatigue, which nearly 40% of patientsscored as 3, 4, or 5; insomnia, with about 30% having high scores;and pain, with about 25% reporting distress (J Pain Symptom Manage10:423-431, 1995).

For lung cancer patients, the correlation between symptom distressand time of survival from diagnosis was -0.49
(P = .0001). Although there were patients with low symptomdistress who had both short and long survival times, virtuallyall of the patients with high symptom distress scores had shortsurvival times.

Of the three outliers (lung cancer patients with high distressclose to time of diagnosis but who were still alive at 5 years),chart review showed that their complaints involved pain in theirthoracotomy scars and/or general surgical site.

"The symptom distress scale is obviously sensitive to theeffects of postsurgical distress, and, as a result, its usefulnessin predicting survival is reduced for such patients," Drs.Degner and Sloan note.

The investigators conclude that measuring symptom distress couldhelp identify lung cancer patients with high distress who mayhave shortened survival regardless of treatment. Such knowledgecan be used to ensure that these patients receive appropriatepalliation and end-of-life counseling. Intervention studies areneeded, they say, to determine whether palliation can increasesurvival.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content